Davis Selected Advisers Buys 702,461 Shares of Solventum Corporation $SOLV

Key Points

• Davis Selected Advisers raised its stake in Solventum by 12.7%, buying 702,461 shares to hold 6,220,072 shares (about 3.59% of the company), with Solventum representing ~2.2% of Davis's portfolio and its 17th largest holding.
• Solventum beat the quarter with $1.57 EPS vs. $1.50 expected and $2.0B revenue vs. $1.96B consensus, set FY2026 guidance of 6.40–6.60 EPS, and trades at a market cap of $11.58B with a P/E of 7.53 while analysts have an average "Hold" rating and $89.45 target.
• Insider Director Amy McBride Wendell purchased 1,475 shares (a 41.4% increase in her stake), and the stock was trading around $66.78 within a 52-week range of $62.38–$88.20 (50-day MA $67.99; 200-day MA $74.48).

Davis Selected Advisers increased its stake in Solventum Corporation (NYSE:SOLV - Free Report) by 12.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,220,072 shares of the company's stock after purchasing an additional 702,461 shares during the period. Solventum makes up approximately 2.2% of Davis Selected Advisers' portfolio, making the stock its 17th biggest holding. Davis Selected Advisers owned approximately 3.59% of Solventum worth $492,880,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Hilltop National Bank grew its position in Solventum by 71.3% during the fourth quarter. Hilltop National Bank now owns 310 shares of the company's stock valued at $25,000 after acquiring an additional 129 shares during the last quarter. Measured Wealth Private Client Group LLC bought a new position in Solventum during the third quarter valued at approximately $25,000. Deseret Mutual Benefit Administrators grew its position in Solventum by 78.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company's stock valued at $27,000 after acquiring an additional 163 shares during the last quarter. JNBA Financial Advisors grew its position in Solventum by 205.4% during the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company's stock valued at $27,000 after acquiring an additional 228 shares during the last quarter. Finally, CYBER HORNET ETFs LLC bought a new position in Solventum during the second quarter valued at approximately $28,000.

Solventum Stock Down 0.9%

Shares of Solventum stock opened at $66.78 on Friday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.89 and a current ratio of 1.23. Solventum Corporation has a 52-week low of $62.38 and a 52-week high of $88.20. The stock has a market capitalization of $11.58 billion, a price-to-earnings ratio of 7.53, a P/E/G ratio of 1.10 and a beta of 0.60. The company's 50 day moving average price is $67.99 and its 200-day moving average price is $74.48.

Solventum (NYSE:SOLV - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The firm had revenue of $2 billion for the quarter, compared to analysts' expectations of $1.96 billion. During the same quarter last year, the business earned $1.41 earnings per share. The business's revenue was down 3.7% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Equities research analysts forecast that Solventum Corporation will post 6.5 EPS for the current year.

Insider Activity

In other news, Director Amy Mcbride Wendell bought 1,475 shares of the business's stock in a transaction dated Tuesday, March 10th. The shares were purchased at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the acquisition, the director owned 5,039 shares of the company's stock, valued at approximately $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.24% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on SOLV shares. BTIG Research reiterated a "buy" rating and set a $100.00 price target on shares of Solventum in a research report on Friday, February 27th. Wall Street Zen cut shares of Solventum from a "buy" rating to a "hold" rating in a research report on Sunday, March 8th. Mizuho set a $100.00 price target on shares of Solventum and gave the company an "outperform" rating in a research report on Tuesday, January 20th. Piper Sandler reduced their price target on shares of Solventum from $98.00 to $92.00 and set an "overweight" rating on the stock in a research report on Friday, April 17th. Finally, KeyCorp reduced their price target on shares of Solventum from $99.00 to $92.00 and set an "overweight" rating on the stock in a research report on Monday. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Solventum has an average rating of "Hold" and an average target price of $89.45.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.